U.S. stock futures were mixed this morning, with the Nasdaq 100 futures gaining around 100 points on Tuesday.

Shares of Telefonaktiebolaget LM Ericsson – ADR (NASDAQ:ERIC) fell sharply in pre-market trading following second-quarter results.

ERIC reported quarterly earnings of 13 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $5.422 billion which missed the analyst consensus estimate of $5.840 billion.

Telefonaktiebolaget LM Ericsson shares dipped 9.2% to $10.64  in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

• Evotec SE (NASDAQ:EVO) shares dipped 18.1% to $1.99 in pre-market trading after declining around 13% on Monday. Evotec announced preliminary second-quarter financial results and updated its full-year 2026 outlook.
• Braiin Ltd (NASDAQ:BRAI) shares dipped 7.8% to $5.93 in pre-market trading. Braiin shares jumped over 16% on Monday after the company announced the release of ARIA.
• Perspective Therapeutics Inc (NYSE:CATX) fell 7.4% to $2.86 in pre-market trading.
• Vicore Pharma Holding AB ADR (NASDAQ:VCRE) declined 6.7% to $11.80 in pre-market trading.
• Q32 Bio Inc (NASDAQ:QTTB) fell 6.5% to $19.99 in pre-market trading after announcing a proposed public offering of common stock and pre-funded warrants.
• Kingsoft Cloud Holdings Ltd (NASDAQ:KC) declined 6.2% to $9.75 in pre-market trading after falling around 5% on Monday.
• Penguin Solutions Inc (NASDAQ:PENG) fell 5% to $73.33 in pre-market trading after the company announced a proposed convertible notes offering.
• Chagee Holdings Ltd (NASDAQ:CHA) declined 5% to $11.09 in pre-market trading after gaining over 6% on Monday.
• Baidu Inc (NASDAQ:BIDU) fell 4.2% to $108.59 in pre-market trading following a 4% decline on Monday.
• SL Science Holding Ltd (NASDAQ:SLBT) slipped 4.1% to $4.15 in pre-market trading after declining over 8% on Monday. SL Science Holding, last week, announced it has submitted an Orphan Drug Designation request to the FDA for its Gamma Delta T cell therapy product, Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.